A U.S. Centers for Disease Control and Prevention advisory panel voted unanimously on Sunday to recommend Johnson & Johnson’s COVID-19 shot for widespread use, a final clearance for the vaccine a day after it was authorized by U.S. regulators.
The Advisory Committee on Immunization Practices (ACIP) voted 12-0 to recommend the adenovirus vector vaccine from J&J as appropriate for Americans 18 and older. There was one abstention due to prior conflicts of interest.
